TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer - Herbst,R.S.; Prager,D.; Hermann,R. (J Clin Oncol, 2005)